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Abstract
Introduction. The pharmacological treatment of ventricular arrhythmias (VA) has significant limitations. Ranolazine is 
a relatively new drug with documented antianginal and anti-ischaemic mechanisms and where preclinical data provides 
evidence of additional antiarrhythmic properties.
The aim of this article was to evaluate the safety and efficacy of ranolazine in patients with recurrent antiarrhythmic 
therapy-refractory VA.
Material and methods. This prospective evaluation included 30 patients (pts) (male/female: 26/4; mean age: 65 ± 10 
years; coronary artery disease/dilated cardiomyopathy: 20/10; New York Heart Association class I/II/III/IV: 2/14/12/2, 
left ventricular ejection fraction: 27 ± 10%; implantable cardioverter-defibrillator (ICD): 15 pts, implantable cardioverter-
-defibrillator with cardiac resynchronisation therapy (CRT-D): 14 pts with recurrent significant VA [ventricular fibrillation, 
sustained ventricular tachycardia (VT) and/or non-sustained VT, multiple ventricular premature complexes > 1,000/ 
/day, biventricular stimulation  (BiV) < 95%] and where standard treatment options, i.e. pharmacotherapy, coronary 
revascularisation, and percutaneous ablation, had proved ineffective. The severity of the arrhythmia was assessed by 
24-hour electrocardiographic (ECG) Holter monitoring and in ICD/CRT-D memory recording. The patients received, in 
addition to the standard pharmacotherapy (amiodarone: 18 pts, beta-blocker: 26 pts) ranolazine 375 mg twice daily 
for three months. Baseline data was compared to the data obtained after the three months of ranolazine treatment.
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Results. We observed a significant reduction of total ventricular extrasystoles determined by ECG Holter monitoring 
(median: 1,737 vs. 1,260, p = 0.04). Similarly, significant VA in ICD/CRT-D memory recording was diminished (67.7 vs. 
35.5%, p = 0.03). The number of ICD interventions in terms of both antitachycardia pacing (9 pts vs. 2 pts, p = 0.01), 
and shock delivery (8 pts vs. 2 pts, p = 0.01), was lower after the three-month observation. The therapy was ineffective 
for nine (29%) patients — two were hospitalised during the three-month follow-up because of recurrent arrhythmia and 
in seven pts there was no noticeable reduction in the amount of VA. Adverse effects, in the form of gastrointestinal 
symptoms (diarrhoea: two, constipation: one), occurred in three (10%) patients.
Conclusions. Authors observed no significant QT prolongation in any patient. There were no differences between the 
baseline and the post-ranolazine patient clinical characteristics. Ranolazine seems to be a safe and effective second-
line therapy in the reduction of VA and ICD interventions in patients with recurrent antiarrhythmic therapy-refractory 
events.
Key words: ranolazine, ventricular arrhythmias, therapy-refractory arrhythmias
Folia Cardiologica 2019; 14, 2: 150–155
Material and methods
This prospective evaluation included a group of 30 pa-
tients enrolled into the study between 2013 and 2018 
(26 male/4 female, mean age: 65 ± 10 years; CAD/DCM: 
20/10; New York Heart Association (NYHA) class: I/II/III/IV: 
2/14/12/2, left ventricular ejection fraction (LVEF): 27 
± 10%; implantable cardioverter-defibrillator (ICD): 15 pts, 
cardiac resynchronisation therapy with defibrillator (CRT-D): 
14 pts) (Table 1), all of whom had recurrent significant 
antiarrhythmic therapy-refractory ventricular arrhythmias.
The inclusion criteria were: ventricular fibrillation (VF), 
sustained (sVT) and/or non-sustained ventricular tachycar-
dia (nsVT), and multiple ventricular premature complexes 
(VEs) obtained after exhausting the standard treatment 
options, i.e. pharmacotherapy, coronary revascularisation 
and percutaneous ablation.
The exclusion criteria were: acute coronary syndrome, 
severe heart failure decompensation, current infection 
of potential significance for the occurrence of ventricular 
arrhythmias, thyroid function abnormalities, hypokalemia, 
implanted device without Holter monitoring, liver failure, 
chronic kidney disease with GFR < 30 ml/min., neurological 
diseases/conditions such as a past history of clinically 
apparent ischaemic stroke, and active subarachnoid ha-
emorrhage.
Of the 30 patients enrolled into the study, 20 suffered 
from coronary artery disease (LVEF: 28 ± 12%, ICD: 9; 
CRT-D: 10) and 10 from dilated cardiomyopathy (LVEF 
25 ± 6%, ICD: 6; CRT-D: 4). In all patients, standard phar-
macotherapy administered according to the current ESC 
guidelines as well as invasive procedures including coro-
nary artery revascularisation and catheter ablation had 
proved ineffective. All patients had been re-hospitalised 
due to recurrent arrhythmia. They were on stable therapy. 
Introduction
Ventricular arrhythmias remain a complex and challenging 
problem. Treatment comprises pharmacotherapy, which 
however has significant limitations, as well as invasive 
procedures such as coronary artery revascularisation and 
catheter ablation.
Therefore, there is a clear need to seek new anti-
-arrhythmic drugs that could be implemented into therapy.
A potential option could be ranolazine. This is a re-
latively new, well-tolerated drug with proven antianginal 
activity [1–3] and with a biochemical structure similar 
to that of lidocaine. As ranolazine is an inhibitor of ion 
channels, it can modify the excitability of atrial and ven-
tricular myocardium cells. It inhibits both extracellular 
(depolarising) currents: sodium (Na+) along with L-type 
calcium channels (Ical), as well as cellular (repolarising) 
potassium (K+) currents. The clinical effects of ranolazine, 
which are based on the protection of the myocardium 
during ischaemia/reperfusion (an antianginal effect), an 
improvement in mechanical dysfunction, and an ‘electri-
cal’ stabilisation of cells, are mainly associated with the 
inhibition of sodium channels.
The anti-arrhythmic activity of ranolazine has been 
recorded among patients with atrial fibrillation [4–6], but 
its role in the treatment of ventricular arrhythmias has not 
yet been fully investigated. It appears that the drug could 
primarily be used in the treatment of such arrhythmias in 
patients with coronary artery disease (CAD), but potentially 
also in other groups, i.e. dilated cardiomyopathy (DCM).
Thus, the aim of our study was to evaluate the safety 
and efficacy of ranolazine in patients with the highest 
risk of sudden cardiac death (SCD) — in patients with 
recurrent antiarrhythmic therapy-refractory ventricular 
arrhythmias.
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All modifications/interventions were done during the pre-
v ious hospitalisation.
These patients received ranolazine 375 mg twice daily 
for three months in addition to their standard pharmaco-
therapy. Eighteen patients were on chronic amiodarone 
therapy.
Clinical assessment, resting ECG, ECG Holter monito-
ring, ICD/CRT-D memory recording, transthoracic echo-
cardiography as well as standard laboratory examinations 
were obtained at baseline and again after three months 
of ranolazine treatment. The severity of the arrhythmia 
was assessed by 24-hour ECG Holter monitoring (signi-
ficant ventricular arrhythmia was defined as: nsVT/VT/ 
/VEs > 1,000/day) and in ICD/CRT-D memory recording 
(significant ventricular arrhythmia was defined as: nsVT/ 
/VT/VF, BiV < 95%).
Baseline data was compared to data obtained after the 
three-month ranolazine treatment.
The study was conducted in accordance with the Dec-
laration of Helsinki and was approved by the local Ethics 
Committee. All patients gave their written consent for 
participation in the study prior to enrollment.
Statistical analysis
Statistical analysis was performed using Statistica 10.0 
(StatSoft Poland) software. Continuous variables were 
presented as median, and categorical as absolute counts 
and percentages. The type of distribution was verified using 
a Shapiro-Wilk test. In cases of normally-distributed variab-
les, Student’s t test for unpaired samples was used, while 
Mann–Whitney U test was implemented in non-normally 
distributed parameters. Wilcoxon test was used for paired 
samples. A p-value of less than 0.05 was considered sta-
tistically significant.
Clinical characteristics
Comparison of the baseline clinical data and the data 
obtained after the three-month ranolazine therapy did 
not reveal any significant changes in the patients’ clinical 
status. We observed no significant improvement in effort 
tolerance expressed in the NYHA scale. In several cases 
we found an improvement in CCS scale (5 pts) as well as 
a reduction of the subjective sensation of palpitations 
(5 pts). The echocardiographic parameters remained simi-
lar after the treatment, including LVEF (28% ± 12 vs. 29% 
± 12, p = NS). The level of potassium remained normal, 
at a stable level (avg. 4.4 mEg/L). Serum NT-proBNP level 
did not significantly change during the observation (median 
value 412 vs. 365 pg/mL).
Efficacy of ranolazine treatment
Significant ventricular arrhythmia determined via Holter 
monitoring was reduced after ranolazine therapy (77.4 
vs. 48.4%, p = 0.01). A significant reduction of total VEs 
was observed in the Holter monitoring (median: 1,737 vs. 
1,260, p = 0.04) (Table 2).
Table 2. Efficacy of ranolazine treatment
Parameter Baseline Post- 
-ranolazine
p value
Total VEs in Holter ECG 
(median)
1,737 1,260 0.04
Ventricular arrhythmia 
in ICD/CRT-D memory 
recording [%]
67.7 35.5 0.03
ATP, N [%] 9 (30) 2 (7) 0.01
Shock delivery, N [%] 8 (27) 2 (7) 0.01
Table 1. Clinical characteristics
Parameter All patients 
N = 30
Patients with CAD 
N = 20
Patients with DCM 
N = 10
Mean value ± SD 
N (%)
Age [years] 65 ± 10 68 ± 7 60 ± 13
Height [cm] 173 ± 9 171 ± 10 176 ± 4
Weight [kg] 87 ± 15 83 ± 14 95 ± 16
BMI [kg/m2] 29 ± 5 29 ± 5 31 ± 5
LVEF [%] 27 ± 10 28 ± 12 25 ± 7
LV EDD [mm] 70 ± 11 69 ± 10 72 ± 12
LV ESD [mm] 58 ± 11 56 ± 11 61 ± 11
ICD 15 (50%) 9 (45%) 6 (60%)
CRT-D 14 (47%) 10 (50% 4 (40%)
DDDR 1 (3%) 1 (5%) 0
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Similarly, significant ventricular arrhythmia in ICD/ 
/CRT-D memory recording was diminished (67.7 vs. 35.5%, 
p = 0.03). The number of ICD interventions in terms of 
both antitachycardia pacing (9 pts vs. 2 pts, p = 0.01) and 
shock delivery (8 pts vs. 2 pts, p = 0.01) was lower after 
the three-month observation (Table 2).
The therapy was ineffective for nine (29%) of the pts 
— two were hospitalised during the three-month follow-up, 
and in seven pts there was no noticeable reduction in the 
amount of ventricular arrhythmia.
Ranolazine treatment: CAD vs. DCM
The total value of VEs in Holter ECG in patients with CAD 
was insignificantly higher at baseline than in cases of DCM 
(median value 1,864 vs. 3,074).
After the ranolazine treatment, we observed a signi-
ficant reduction in total VE values determined via Holter 
ECG in the CAD patients (median value 1,864 vs. 1,271, 
p < 0.05).
In the group of patients with DCM, a reduction in total 
VE values was observed in five cases (50%, median value 
6,460 vs. 500), although the result was statistically non-
-significant for the whole subgroup (median value 3,074 vs. 
2,000) (Figure 1).
Ranolazine treatment: amiodarone  
vs. non-amiodarone
The total value of VEs determined via Holter ECG in patients 
treated with amiodarone was insignificantly lower than the 
value in subjects without amiodarone at baseline (1,529 
vs. 4,100).
In the group of patients treated with amiodarone, we 
observed a significant reduction in total VEs in Holter ECG 
(median value 1,529 vs. 500, p < 0.05).
In the group of patients treated with ranolazine without 
amiodarone, we observed reduced total VEs in Holter ECG 
in five cases (42%, median value 5,000 vs. 1,281), but the 
efficacy of the drug was statistically insignificant for the 
whole subgroup (median value 4,100 vs. 1,281).
Safety of ranolazine treatment
Adverse effects in the form of gastrointestinal symptoms 
(diarrhoea: two, constipation: one) occurred in three (10%) 
pts. We observed no significant QT prolongation in any 
patient, and no significant changes in the average heart 
rate (66 ± 8 vs. 63 ± 9 bpm, p = 0.31).
Discussion
The crucial finding of our research is that ranolazine can 
be used effectively as a second-line therapy in ventricular 
arrhythmias. 
The drug was effective with statistical significance in 
patients with CAD. Perhaps this was due to its better ef-
fect in people with this disease; however, due to the small 
number of patients in the study group, further research is 
needed to objectify this claim.
It should be noted that we analysed a very specific group 
of patients. Our study group consisted of patients with the 
highest risk of SCD — patients with recurrent antiarrhythmic 
therapy-refractory ventricular arrhythmias. Both standard 
pharmacotherapy and invasive procedures had proved 
ineffective. Ranolazine was administered over and above 
the current available therapy.
Additionally, all subjects presented symptoms of chronic 
heart failure with a reduced ejection fraction. Regardless 
of their stable haemodynamic status, the LVEF was below 
30% in most of the patients. All these figures underline the 
clinical importance of our findings.
Whereas until now the efficacy of the drug has been 
proved in atrial fibrillation [4–6], studies are still ongoing re-
garding its possible use in ventricular arrhythmias. A recently 
completed RAID trial in which a comparable group of patients 
was enrolled into the study showed however that in high-risk 
ICD patients, treatment with ranolazine did not significantly 
reduce the incidence of the first VT or VF or death. 
But, in prespecified secondary endpoint analyses similar 
to our study, ranolazine administration has been associated 
witha significant reduction in recurrent VT or VF requiring ICD 
therapy, without evidence for increased mortality [7]. Another 
study, conducted by Yeung E et al., showed a significant re-
duction in median premature ventricular complexes burden, 
as well as the elimination of VT in chosen patients and the 
prevention of recurrent defibrillator therapy, something which 
was also found in our study [8]. The efficacy of ranolazine in 
the treatment of ventricular arrhythmias has also been ob-
served in patients with symptomatic non-obstructive hyper-
trophic cardiomyopathy. Olivotto et al. [9] examined a group 
Figure 1. Median value of total ventricular extrasystoles in elec-
trocardiographic Holter monitoring before and post-ranolazine 
treatment; CAD — coronary artery disease; DCM — dilated cardio-
myopathy
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of 80 patients who were treated with ranolazine 1,000 mg 
bid for five months. However, their primary endpoint was to 
observe possible changes in peak VO2 compared to baseline 
using a cardiopulmonary exercise test. The severity of the 
ventricular arrhythmia was also assessed, and a significant 
reduction was observed in the 24-hour burden of premature 
ventricular complexes compared to a placebo [9].
It is worth mentioning that several studies have demon-
strated the additional efficacy of ranolazine treatment in 
combination with amiodarone or dronedarone. Although 
differences have been observed in atrial fibrillation, from 
our study it appears that a similar relationship exists in the 
case of severe ventricular arrhythmias [5, 10, 11].
Overall, in the vast majority of studies, ranolazine has 
proved to be safe and well tolerated.
We are aware of some limitations of our study, of which 
the most important remains the relatively small group of 
patients enrolled. This was because the study included 
patients with both advanced cardiac insufficiency and 
an exhausted option of standard therapy. It seems safe 
to assume that this is inherently a rare group. It should 
probably be contemplated using higher doses of the drug 
to investigate possible intensification of its action.
Conclusion
Ranolazine seems to be an effective and safe second-line 
therapy in reducing the number of ventricular arrhythmia 
episodes and ICD interventions in patients with recurrent 
antiarrhythmic therapy-refractory events. Further research 
is however needed in order to provide more evidence.
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Streszczenie
Wstęp. Farmakologiczne leczenie komorowych zaburzeń rytmu (VA) jest ograniczone. Ranolazyna to stosunkowo nowy 
lek o udokumentowanym działaniu przeciwdławicowym i przeciwniedokrwiennym oraz z danymi przedklinicznymi wska-
zującymi na dodatkowe właściwości antyarytmiczne.
Celem pracy była ocena bezpieczeństwa i skuteczności ranolazyny u pacjentów z nawracającymi opornymi na leczenie VA.
Materiał i metody. Prospektywną oceną objęto 30 pacjentów (pts) (mężczyźni/kobiety: 26/4, średnia wieku: 65 ± 10 lat; 
choroba wieńcowa/kardiomiopatia rozstrzeniowa: 20/10, klasa I/II/III/IV według New York Heart Association: 
2/14/12/2, frakcja wyrzutowa lewej komory: 27 ± 10%; kardiowerter-defibrylator [ICD]: 15 pts, terapia resynchronizu-
jąca serce z funkcją defibrylacji [CRT-D]: 14 pts) z nawracającymi istotnymi VA (migotanie komór, utrwalony częstoskurcz 
komorowy [VT] i/lub nieutrwalony VT, liczne pojedyncze ekstrasystolie komorowe > 1000/d., stymulacja biwentrikularna 
(BiV) < 95%) i z wyczerpaną standardową opcją leczenia, tj. farmakoterapią, rewaskularyzacją wieńcową i przezskórną 
ablacją. Nasilenie arytmii oceniano w 24-godzinnym monitorowaniu elektrokardiograficznym (EKG) metodą Holtera oraz 
w pamięci holterowskiej ICD/CRT-D. U pacjentów do standardowej farmakoterapii (amiodaron: 18 pts, beta-adrenolityk: 
26 pts) dołączono ranolazynę w dawce 375 mg 2 razy/dobę przez 3 miesiące. Wyjściowe dane porównano z danymi 
uzyskanymi po 3-miesięcznym leczeniu.
Wyniki. Autorzy zaobserwowali istotną redukcję liczby ekstrasystolii komorowych w monitorowaniu EKG metodą Holtera 
(mediana: 1737 v. 1260; p = 0,04). Podobnie odnotowano istotne zmniejszenie częstości istotnej VA w zapisie pa-
mięci ICD/CRT-D (67,7 v. 35,5%; p = 0,03). Liczba interwencji ICD zarówno pod względem stymulacji antyarytmicznej 
(9 pts v. 2 pts; p = 0,01), jak i wyładowań (8 pts v. 2 pts; p = 0,01) była niższa po 3-miesięcznej obserwacji. Terapia 
była nieskuteczna u 9 (29%) pacjentów — 2 hospitalizowano w trakcie 3-miesięcznej obserwacji z powodu nawrotu VA, 
a u 7 nie stwierdzono zauważalnego zmniejszenia występowania VA. Działania niepożądane pod postacią dolegliwości 
żołądkowo-jelitowych (biegunka: 2, zaparcie: 1) wystąpiło u 3 (10%) chorych. U żadnego z pacjentów nie obserwowano 
istotnego wydłużenia odstępu QT. Nie obserwowano istotnych różnic w charakterystyce klinicznej pacjentów wyjściowo 
i po podaniu ranolazyny.
Wnioski. Ranolazyna wydaje się bezpiecznym i skutecznym lekiem drugiego rzutu, który może być stosowany w redukcji 
VA i liczby interwencji ICD u pacjentów z nawracającymi opornymi na leczenie VA.
Słowa kluczowe: ranolazyna, arytmie komorowe, arytmie oporne na leczenie
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